期刊
JOURNAL OF CARDIOLOGY
卷 64, 期 3-4, 页码 236-239出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jjcc.2013.12.008
关键词
lntravascular ultrasound/Doppler; Coronary artery disease; Plaque; Fish oils; Cholesterol-lowering drugs
Background and purpose: Many clinical trials have shown that 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) can significantly reduce coronary artery disease in both primary and secondary prevention. A recent study showed that aggressive lipid-lowering therapy with strong statins could achieve coronary artery plaque regression, as evaluated with gray-scale intravascular ultrasound (IVUS). However, it is unknown whether coronary plaque regression and stabilization are reinforced when eicosapentaenoic acid (EPA) is used with a strong statin. Methods and subjects: We aim to assess patients with stable angina or acute coronary syndrome who had undergone successful percutaneous coronary intervention (PCI) with integrated backscatter IVUS (IB-IVUS) guidance. They will be randomly allocated to receive pitavastatin (4 mg), or pitavastatin (4 mg) plus EPA (1800 mg), and prospectively followed for 6-8 months. Results: The primary endpoint will be changes in tissue characteristics in coronary plaques, evaluated by IB-IVUS, and secondary endpoints will include absolute changes in coronary plague volume, serum lipid levels, and inflammatory markers. The safety profile will also be evaluated. Conclusions: The combination therapy of EPA and pitavastatin for regression of coronary plaque evaluated by IB-IVUS (CHERRY) study will be the first multicenter study using IB-IVUS to investigate the effects of combination therapy with pitavastatin and EPA on coronary plaque volume and tissue characteristics. (C) 2014 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据